{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:51:01Z","timestamp":1787496661029,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the adverse events (AEs) lacks of harmonized algorithms during treatment of these patients. We have studied the incidence of relevant AEs of 43 patients who achieved a response to VenHMA and its management. Median overall survival of our cohort was 19\u00a0months. No patients discontinued treatment due to AEs after C3D1, Regarding severe AEs, high rates of grade 4 neutropenia (97.6%) and grade 4 thrombocytopenia (65.1%) were observed. Severe infectious AEs rate was 16%. Due to severe myelotoxicity, most patients required a progressive dose reduction of both venetoclax and hypomethylating agents during follow-up, being 87.8% at C6D1. Transfusional dependence rate was 91% and G-CSF was prescribed to 86% of the patients. Finally, there was not a significant difference in hemoglobin, platelets and absolute neutrophil count after achieving complete response comparing paired samples during follow-up, although cytopenia rate was high during initial follow-up. We conclude that dose reduction of VenHMA after achieving a response in patients diagnosed with AML is required in most patients and essential to avoid prolonged cytopenia-related adverse events and a rapid and standardized method on how to perform it might decrease the AEs rate.<\/jats:p>","DOI":"10.1007\/s00277-024-05923-5","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T02:02:37Z","timestamp":1724896957000},"page":"4033-4043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study"],"prefix":"10.1007","volume":"103","author":[{"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ares","family":"Guardia-Torrelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Isabel","family":"P\u00e9rez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casta\u00f1o-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cort\u00e9s-Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Merch\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Brillembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mun\u00e1rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Zugasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"5923_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"5923_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"J Seymour","year":"2018","unstructured":"Seymour J et al (2018) Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378:1107\u20131120","journal-title":"N Engl J Med"},{"issue":"S2","key":"5923_CR3","first-page":"197","volume":"5","author":"C Jimenez-Vicente","year":"2021","unstructured":"Jimenez-Vicente C et al (2021) Real-life preliminary experience of treatment of newly-diagnosed and refractory\/relapsed (R\/R) acute myeloid leukemia patients with combination of venetoclax with hypomethylating agents. Hemasphere 5(S2):197\u2013198","journal-title":"Hemasphere"},{"key":"5923_CR4","unstructured":"Brillembourg H et al (2022) Infecciones durante el tratamiento de venetoclax e hipometilantes diagnosticados de leucemia mieloide aguda (LMA). Sangre (Barc) 41(Suplem):57\u201358"},{"key":"5923_CR5","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7:e724\u2013e736","journal-title":"Lancet Haematol"},{"key":"5923_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH (2020) How I treat acute myeloid leukemia in the era of new drugs. Blood 135:85\u201396","journal-title":"Blood"},{"key":"5923_CR7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.890.890","volume":"130","author":"A Wei","year":"2017","unstructured":"Wei A et al (2017) Phase 1\/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood 130:890","journal-title":"Blood"},{"key":"5923_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH et al (2019) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol Off J Am Soc Clin Oncol 37:1277\u20131284","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5923_CR9","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","volume":"5","author":"L Masarova","year":"2021","unstructured":"Masarova L et al (2021) Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5:2156\u20132164","journal-title":"Blood Adv"},{"key":"5923_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H et al (2023) Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol 16:42","journal-title":"J Hematol Oncol"},{"key":"5923_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ et al (2024) Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML. J Clin Oncol 42:1499\u20131508","journal-title":"J Clin Oncol"},{"key":"5923_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA et al (2023) A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-Mutated myeloid malignancies. Blood Cancer Discov 4:276\u2013293","journal-title":"Blood Cancer Discov"},{"key":"5923_CR13","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N et al (2022) Venetoclax plus gilteritinib for FLT3-Mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol 40:4048\u20134059","journal-title":"J Clin Oncol"},{"key":"5923_CR14","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M et al (2022) Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood 140:2594\u20132610","journal-title":"Blood"},{"key":"5923_CR15","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC et al (2020) Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol 38:3506\u20133517","journal-title":"J Clin Oncol"},{"key":"5923_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD et al (2022) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97:1035\u20131043","journal-title":"Am J Hematol"},{"key":"5923_CR17","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM et al (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8:e552\u2013e561","journal-title":"Lancet Haematol"},{"key":"5923_CR18","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","volume":"62","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP et al (2021) Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma 62:3394\u20133401","journal-title":"Leuk Lymphoma"},{"key":"5923_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA et al (2022) Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant 57:160\u2013166","journal-title":"Bone Marrow Transplant"},{"key":"5923_CR20","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.2217\/fon-2022-0450","volume":"18","author":"V Ivanov","year":"2022","unstructured":"Ivanov V et al (2022) Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Futur Oncol 18:2879\u20132889","journal-title":"Futur Oncol"},{"key":"5923_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00277-021-04674-x","volume":"101","author":"P Zhao","year":"2022","unstructured":"Zhao P et al (2022) Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 101:119\u2013130","journal-title":"Ann Hematol"},{"key":"5923_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW et al (2024) Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99:615\u2013624","journal-title":"Am J Hematol"},{"issue":"11","key":"5923_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"D Arber","year":"2022","unstructured":"Arber D et al (2022) International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"key":"5923_CR24","doi-asserted-by":"publisher","unstructured":"Khoury JD et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"12","key":"5923_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"5923_CR26","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649","journal-title":"J Clin Oncol"},{"key":"5923_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753\u20132767","journal-title":"Blood"},{"key":"5923_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"5923_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039","author":"DA Pollyea","year":"2020","unstructured":"Pollyea DA et al (2020) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"5923_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2022-158518","volume":"140","author":"KW Pratz","year":"2022","unstructured":"Pratz KW et al (2022) Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood 140:529\u2013531","journal-title":"Blood"},{"key":"5923_CR31","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood-2022-169509","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H et al (2022) ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood 140:1441\u20131444","journal-title":"Blood"},{"key":"5923_CR32","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA et al (2022) Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Res 28:2753\u20132761","journal-title":"Clin Cancer Res"},{"key":"5923_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803","journal-title":"Blood"},{"key":"5923_CR34","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M et al (2021) Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv 5:1552\u20131564","journal-title":"Blood Adv"},{"key":"5923_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317","journal-title":"Blood"},{"key":"5923_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081684","volume":"10","author":"M Piccini","year":"2021","unstructured":"Piccini M et al (2021) Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience. J Clin Med 10:1684","journal-title":"J Clin Med"},{"key":"5923_CR37","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E et al (2020) Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol 95:1511\u20131521","journal-title":"Am J Hematol"},{"key":"5923_CR38","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC et al (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3:2911\u20132919","journal-title":"Blood Adv"},{"issue":"13","key":"5923_CR39","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH et al (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6(13):3997\u20134005","journal-title":"Blood Adv"},{"issue":"7","key":"5923_CR40","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/cancers14071734","volume":"14","author":"J Labrador","year":"2022","unstructured":"Labrador J et al (2022) Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA registry experience. Cancers 14(7):1734","journal-title":"Cancers"},{"key":"5923_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106314","volume":"90","author":"D Gaut","year":"2020","unstructured":"Gaut D et al (2020) Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: A single institution experience. Leuk Res 90:106314","journal-title":"Leuk Res"},{"issue":"4","key":"5923_CR42","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/pharmaceutics14040694","volume":"14","author":"ED Eisenmann","year":"2022","unstructured":"Eisenmann ED et al (2022) Interaction of antifungal drugs with CYP3A- and OATP1B-mediated Venetoclax elimination. Pharmaceutics 14(4):694","journal-title":"Pharmaceutics"},{"key":"5923_CR43","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","volume":"3","author":"I Aldoss","year":"2019","unstructured":"Aldoss I et al (2019) Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv 3:4043\u20134049","journal-title":"Blood Adv"},{"key":"5923_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK et al (2017) Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39:359\u2013367","journal-title":"Clin Ther"},{"key":"5923_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216\u2013228","journal-title":"Lancet Oncol"},{"key":"5923_CR46","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33:2795\u20132804","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05923-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T05:07:14Z","timestamp":1729919234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5923"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05923-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CJV serves as educational speaker for AbbVie and received travel grants from AbbVie, Jazz Pharmaceuticals and Pfizer. FG serves as educational speaker for AbbVie. AMR serves as a consultant or in an advisory role, for Bristol Myers Squibb (BMS), AbbVie, and Kite Gilead; received travel grants from Kite Gilead, Roche, Takeda, Janssen, and AbbVie; and serves as a speaker for AbbVie and Gilead. MDB serves as a consultant for, in an advisory role for, received travel grants from, or served as speaker for BMS, AbbVie, Astellas, JazzPharma, Takeda, and Novartis. JE declares consultancy honoraria from AbbVie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, and Daichii-Sankyo, and received research grants from Novartis, Jazz Pharmaceuticals, and Pfizer. The remaining authors declare no competing financial interests. The founders had no role in the design of the study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Hospital Cl\u00ednic de Barcelona and conducted following standards set forth by the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided their informed consent for the use of laboratory results and genetic analyses.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}